cas 23877-12-5|| where to buy tert-Butyl 2-bromoisobutyrate

製品名:tert-Butyl 2-bromoisobutyrate

IUPAC Name:tert-butyl 2-bromo-2-methylpropanoate

包装単位	有効在庫	価格（USD）
CM361119-500g	in stock	ƎȺ
CM361119-1000g	in stock	ȡǶȐ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 23877-12-5 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:23877-12-5; 分子式:C8H15BrO2; 融点:-; SMILESコード:CC(C)(Br)C(OC(C)(C)C)=O; 密度:

: カタログ番号:CM361119; 分子量:223.11; 沸点:; MDL番号:MFCD00051908; 保管方法:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Elafibranor; Nov 13, 2023, ELATIVE® Phase III trial confirms potential for investigational elafibranor as a first-in-class, dual PPAR α,δ agonist for patients with Primary Biliary Cholangitis.
Elafibranor is a novel, oral, once-daily, dual peroxisome activated receptor (PPAR) alpha/delta (α,δ) agonist, currently under investigation as a treatment for patients with PBC, a rare liver disease. Concurrent α,δ activation targets inflammation, cholestasis and fibrosis in PBC.